Lantheus Holdings, Inc.
LNTH
Positions held
Your positionsLNTH isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Lantheus Holdings is positioned well in the healthcare sector, focusing on innovative diagnostic imaging agents that cater to the growing demand for advanced medical imaging solutions.
- In Q2 2026, Lantheus reported a revenue increase of 3% compared to the previous quarter, reaching $388 million.
- The company's operating margin expanded to 25.8% in Q2 2026, indicating improved operational efficiency.
- Despite its growth potential, Lantheus faces challenges with a declining earnings growth rate, which may raise concerns among investors.
- The net income for Q1 2026 was $118.417 million, down from $75.029 million in Q2 2026, reflecting volatility in profitability.
- The trailing P/E ratio stands at 24.26, suggesting that the stock may be overvalued compared to its earnings growth.
Fundamentals
| Market cap | $6.54B | Enterprise value | $6.57B | Trailing P/E | 24.24 | Forward P/E | 15.70 |
| PEG | — | Price / book | 4.98 | Beta | -0.06 | Dividend yield | 0.00% |
| Revenue growth | 2.7% | Earnings growth | -0.9% | Gross margin | 60.1% | Operating margin | 25.8% |
| Profit margin | 17.7% | ROE | 22.2% | ROA | 8.4% | Debt / equity | 0.48 |
| Current ratio | 3.06 | Free cash flow | $451.66M | Analyst recommendation | buy | Mean target | $107.74 |
| 52w high | $111.86 | 52w low | $50.16 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $388M | $377M | $407M | $384M | $378M | — |
| Op margin | 25.8% | 21.6% | 19.0% | 11.4% | 23.3% | — |
| Net income | $75.0M | $118M | $54.1M | $27.8M | $78.8M | — |
| Gross margin | 62.3% | 61.2% | 59.2% | 57.9% | 63.8% | — |
| Gross profit | $242M | $231M | $241M | $222M | $241M | — |
| Operating income | $100M | $81.3M | $77.2M | $43.6M | $88.0M | — |
- Revenue +3% vs prior quarter ($388M vs $377M).
- Gross margin 62.3% (was 61.2% prior quarter).
- Operating margin expanded to 25.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $1.5B | $1.5B | $1.3B | $935M |
| Op margin | 20.5% | 29.2% | 28.1% | 3.9% |
| Net income | $234M | $312M | $327M | $28.1M |
| Gross margin | 61.1% | 64.4% | 54.7% | 62.2% |
| Gross profit | $942M | $988M | $710M | $582M |
| Operating income | $316M | $449M | $365M | $36.2M |
Headlines — watch
• [WARN · legal] Lantheus Says Curium Resubmits Antitrust Filing for Merger
News
2026-10-06 · 1 Healthcare Stock with Exciting Potential and 2 We Find Risky
2026-10-05 · GE HealthCare to Buy Sofie for Nearly $1 Billion to Grow Medical-Imaging Business
2026-09-30 · Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
2026-09-28 · Lantheus Doses First Patient in Phase 2/3 Prostate Cancer Trial
2026-09-28 · Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
2026-09-26 · Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval
2026-09-26 · Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval
2026-09-23 · Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally
2026-09-23 · 3 Reasons LNTH is Risky and 1 Stock to Buy Instead
2026-09-22 · Lantheus Says FDA Approves Cancer Drug
2026-09-22 · Lantheus Says Curium Resubmits Antitrust Filing for Merger
Price (daily)
Full chart · RSI · MACD · patterns